| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Over the last 12 months, insiders at Celularity Inc. have bought $0 and sold $0 worth of Celularity Inc. stock.
On average, over the past 5 years, insiders at Celularity Inc. have bought $4.24M and sold $23.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 21,410,983 shares for transaction amount of $5.33M was made by Lim Kok Thay (10 percent owner) on 2024‑01‑12.
| 2024-01-12 | Lim Kok Thay | 10 percent owner | 21.41M 11.8762% | $0.25 | $5.33M | +38.71% | ||
| 2023-10-05 | Sale | Sorrento Therapeutics, Inc. | 10 percent owner | 6.31M 21.0749% | $1.50 | $9.46M | +42.18% | |
| 2023-10-05 | Hariri Robert J | Chief Executive Officer | 9.36M 3.306% | $0.16 | $1.48M | +42.18% | ||
| 2023-09-29 | Sale | Sorrento Therapeutics, Inc. | 10 percent owner | 9.06M 30.2885% | $1.50 | $13.6M | +35.14% | |
| 2023-09-29 | Hariri Robert J | Chief Executive Officer | 9.06M 3.3418% | $0.17 | $1.5M | +35.14% | ||
| 2022-11-30 | Hariri Robert J | Chief Executive Officer | 10,000 0.0383% | $1.72 | $17,175 | -66.08% | ||
| 2022-11-29 | Hariri Robert J | Chief Executive Officer | 40,000 0.1524% | $1.71 | $68,400 | -65.27% | ||
| 2022-11-28 | Hariri Robert J | Chief Executive Officer | 40,000 0.155% | $1.74 | $69,600 | -64.36% |
| Lim Kok Thay | 10 percent owner | 51473762 177.8269% | $86.48M | 1 | 0 | +38.71% |
| Hariri Robert J | Chief Executive Officer | 28570434 98.7025% | $48M | 5 | 0 | <0.0001% |
| Sorrento Therapeutics, Inc. | 10 percent owner | 5050427 17.4478% | $8.48M | 0 | 2 |
$2,542,362 | 111 | 11.81% | $42.37M | |
$155,630,608 | 79 | -24.53% | $56.52M | |
$693,326 | 47 | -16.24% | $47.49M | |
$24,478,755 | 37 | -34.59% | $49.2M | |
$226,127 | 22 | -27.62% | $45.57M | |
$352,389 | 18 | 9.66% | $33.23M | |
$91,696,644 | 18 | -4.72% | $46.96M | |
$20,234,041 | 17 | 2.09% | $40.57M | |
$17,594,514 | 16 | -20.37% | $57.99M | |
$20,042,003 | 10 | -19.50% | $54.7M | |
$45,000,000 | 6 | -31.22% | $51.41M | |
Celularity Inc. (CELU) | $8,470,804 | 6 | -13.28% | $48.63M |
$208,889 | 5 | 44.22% | $48.76M | |
$26,254,149 | 5 | 49.97% | $38.43M | |
$5,306,958 | 5 | 11.70% | $36.3M | |
$657,791 | 4 | -52.05% | $59.13M | |
$1,499,988 | 3 | 0.92% | $35.41M | |
$19,175,155 | 2 | 40.00% | $55.39M | |
$12,498 | 2 | 39.61% | $51.46M |
| Increased Positions | 11 | +25.58% | 172,615 | +7.51% |
| Decreased Positions | 12 | -27.91% | 258,928 | -11.26% |
| New Positions | 4 | New | 92,747 | New |
| Sold Out Positions | 6 | Sold Out | 194,266 | Sold Out |
| Total Postitions | 42 | -2.33% | 2M | -3.75% |
| C V Starr & Co Inc | $925.00 | 2.73% | 764,069 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $819.00 | 2.42% | 676,650 | +176,518 | +35.29% | 2025-09-30 |
| Geode Capital Management, Llc | $169.00 | 0.5% | 139,314 | +4,489 | +3.33% | 2025-09-30 |
| Blackrock, Inc. | $126.00 | 0.37% | 103,833 | +768 | +0.74% | 2025-09-30 |
| Yorkville Advisors Global, Lp | $121.00 | 0.36% | 100,000 | -100,000 | -50% | 2025-09-30 |
| State Street Corp | $70.00 | 0.21% | 57,830 | -7,600 | -11.62% | 2025-09-30 |
| Valmark Advisers, Inc. | $60.00 | 0.18% | 49,983 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $54.00 | 0.16% | 44,756 | -15,012 | -25.12% | 2025-09-30 |
| Renaissance Technologies Llc | $51.00 | 0.15% | 42,000 | +29,800 | +244.26% | 2025-09-30 |
| Hb Wealth Management, Llc | $49.00 | 0.14% | 40,415 | +40,415 | New | 2025-09-30 |